Clinical Trials Directory

Trials / Unknown

UnknownNCT00728546

NAT2 in Re-challenge of INH in Patients With Hepatitis

The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Apply the information of NAT2 genotyping into the re-challenge protocol of INH titration in patients with anti-TB medication induced hepatitis.

Detailed description

adjusting INH dose according to NAT2 genotyping and serum concentration of INH.

Conditions

Interventions

TypeNameDescription
DRUGIsoniazid (Rifinah)The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.

Timeline

Start date
2008-06-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2008-08-06
Last updated
2012-12-27

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT00728546. Inclusion in this directory is not an endorsement.